GB221

DRUG3 trials

Sponsors

Genor Biopharma Co., Ltd., Gemma Biotherapeutics

Conditions

Breast CancerHER-2-positive Advanced Breast CancerSpinal Muscular Atrophy Type I

Phase 1

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

CompletedNCT04905667

Genor Biopharma Co., Ltd.Breast Cancer

Start: 2019-11-13End: 2020-09-11Updated: 2021-05-27

Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1

RecruitingNCT07070999

Gemma BiotherapeuticsSpinal Muscular Atrophy Type I

Start: 2026-01-06End: 2029-04-01Target: 22Updated: 2026-06-29

Phase 3

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection

Genor Biopharma Co., Ltd.HER-2-positive Advanced Breast Cancer

Start: 2016-11-24End: 2020-11-30Target: 336Updated: 2019-11-15